Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |